Sofinnova Investments, Inc. Macrogenics Inc Transaction History

Sofinnova Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $4.63 Million - $6.73 Million	-234,504 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $3.31 Million - $5.75 Million	161,303 Added 220.36%	234,504 $6.3 Million
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $7.32 Million - $12.8 Million	-385,606 Reduced 84.05%	73,201 $2.33 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $8.91 Million - $11.9 Million	458,807 New	458,807 $10.5 Million
Q1 2020 May 13, 2020	SELL	$4.28 - $12.11 $5.02 Million - $14.2 Million	-1,173,882 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $4.71 Million - $7.27 Million	592,328 Added 101.85%	1,173,882 $12.8 Million
Q3 2019 Nov 14, 2019	BUY	$12.44 - $17.48 $387,020 - $543,820	31,111 Added 5.65%	581,554 $7.42 Million
Q2 2019 Aug 13, 2019	BUY	$14.51 - $19.71 $387,228 - $526,000	26,687 Added 5.1%	550,443 $9.34 Million
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $2.12 Million - $4.89 Million	190,835 Added 57.32%	523,756 $9.42 Million
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $3.91 Million - $7.13 Million	332,921 New	332,921 $4.23 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.